With some 12 years as CEO under his belt, Bavarian Nordic’s Paul Chaplin is telegraphing his exit from the Denmark-based ...

Since the start of the millennium, podcasts have gone from nonexistent to numbering in the millions, and Edison Research ...

Following an extensive Middle East military build-up by the U.S. in recent weeks, the U.S. and Israel on Feb. 28 launched attacks across Iran. In response, Iran launched retaliatory attacks on Israel, ...

As it ramps up its rollout of the first twice-yearly HIV pre-exposure prophylaxis (PrEP) medicine, Gilead Sciences is tapping into a beloved early-aughts track to familiarize consumers with Yeztugo.

Ahead of a rescheduled meeting of the Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP), Department of Health and Human Services (HHS) Secretary | ...

Ascendis Pharma is spiraling upward by way of its TransCon platform. | Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based ...

Quotient Sciences, a CDMO that specializes in "niche and smaller volume" drugs that it says are often overlooked by bigger contract manufacturers, has ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

Chinese assets have outgrown a “bargain basement” label as the upfront value of licensing deals involving them has increased, ...

While the FDA has flip-flopped on whether to review Moderna’s combination influenza and COVID-19 vaccine, it’s full speed ...

The committee’s reputation has taken a nosedive, however, following HHS Secretary Robert F. Kennedy Jr.’s decision to purge ...

Sarepta Therapeutics CEO Doug Ingram announced Wednesday that he will retire by the end of 2026, citing a “shocking and ...